• Karen E Mate, Michelle Barnett, Karen P Kerr, C Dimity Pond, and Parker J Magin.
• School of Biomedical Sciences and Pharmacy and, Callaghan, Australia.
• Fam Pract. 2020 Jul 23; 37 (3): 314-320.

BackgroundIt is recommended that anticholinergic medication is avoided in older people, especially those with cognitive impairment.ObjectiveTo investigate anticholinergic load (ACL) over time in older primary care patients with and without cognitive impairment.MethodsCommunity-dwelling general practice patients at baseline (n = 1768), at year one (n = 1373) and a restricted cohort (with possible or definite cognitive impairment) at year two (n = 370) had medication regimens documented by a research nurse during a home visit. Anticholinergic medicines were categorized as levels 1-3 (low-high potency) and summed for each participant as a measure of their ACL.ResultsMost participants had no change in ACL over time, but there was some turnover in the anticholinergic medications used. The mean change in ACL was 0.012 ± 0.99 from baseline to 12 months and -0.04 ± 1.3 from baseline to 24 months. Cardiovascular drugs were the most commonly used level 1 anticholinergics, followed by antidepressants and opioids. Antidepressants and urologicals were the most commonly used level 3 anticholinergics. The rate of anticholinergic deprescribing was equivalent to the rate of anticholinergic initiation, and commonly involved the level 1 drugs warfarin, furosemide and temazepam, and the level 3 drugs amitriptyline and oxybutynin. People with dementia had a higher ACL at baseline and year one compared with other participants.ConclusionACL of community-dwelling older people was very stable over time. This may represent lost opportunities for deprescribing as well as potentially inappropriate prescribing, particularly in those with cognitive impairment.© The Author(s) 2019. Published by Oxford University Press. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.

23 keywords...

hide…